Abstract
We have demonstrated that caspase-1-deficient (caspase-1–/–) mice are functionally and histologically protected against cisplatin-induced acute renal failure (ARF). Caspase-1 exerts proinflammatory effects via the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil recruitment. We sought to determine the role of the cytokines IL-1β, IL-18, and IL-6 and neutrophil recruitment in cisplatin-induced ARF. We first examined IL-1β; renal IL-1β increased nearly 2-fold in cisplatin-induced ARF and was reduced in the caspase-1–/– mice. However, inhibition with IL-1 receptor antagonist (IL-1Ra) did not attenuate cisplatin-induced ARF. Renal IL-18 increased 2.5-fold; however, methods to inhibit IL-18 using IL-18 antiserum and transgenic mice that overproduce IL-18-binding protein (a natural inhibitor of IL-18) did not protect. Renal IL-6 increased 3-fold; however, IL-6-deficient (IL-6–/–) mice still developed cisplatin-induced ARF. We next examined neutrophils; blood neutrophils increased dramatically after cisplatin injection; however, prevention of peripheral neutrophilia and renal neutrophil infiltration with the neutrophil-depleting antibody RB6-8C5 did not protect against cisplatin-induced ARF. In summary, our data demonstrated that cisplatin-induced ARF is associated with increases in the cytokines IL-1β, IL-18, and IL-6 and neutrophil infiltration in the kidney. However, inhibition of IL-1β, IL-18, and IL-6 or neutrophil infiltration in the kidney is not sufficient to prevent cisplatin-induced ARF.
Footnotes
-
This work was supported by National Institutes of Health Grants K08 DK65022-01 (to S.F.) and R01 DK56851 (to C.L.E.) and a grant from Chung-Ang University, Department of Internal Medicine, Seoul, Korea (to D.-J.O.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.119792.
-
ABBREVIATIONS: ARF, acute renal failure; IL, interleukin; BUN, blood urea nitrogen; IL-1Ra, IL-1 receptor antagonist; IL-18BP, IL-18-binding protein; Tg, transgenic; ELISA, enzyme-linked immunosorbent assay; ATN, acute tubular necrosis; PAS, periodic acid-Schiff; ANAb, anti-neutrophil antibody; PBS, phosphate-buffered saline; caspase-1–/–, caspase-1-deficient; AS, antiserum; ECL, electrochemiluminescence; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; WY-14,643, [4-chloro-6(2,3-xylidino)-2-pyrimidinylthio] acetic acid.
- Received January 10, 2007.
- Accepted March 29, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|